This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (184)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Osteoporosis  • Women's Health, Other  • Alert me on articles by topic

Scientific Review

Steven R. Cummings, MD; David Bates, MD,MSc; Dennis M. Black, PhD

JAMA. 2002;288:1889-1897.

Context  Osteoporosis causes substantial morbidity and costs $13.8 billion annually in the United States. Measurement of bone mass by densitometry is a primary part of diagnosing osteoporosis and deciding a preventive treatment course. Bone mineral densitometry has become more widely available and commonly used in practice.

Objective  To review evidence about the value of various clinical applications of bone densitometry.

Data Sources  A MEDLINE search was performed to update previous meta-analyses of the relationship between various measurements of bone density and risk of vertebral and hip fracture. We used data from the prospective Study of Osteoporotic Fractures to estimate risk of fracture from bone density and age in postmenopausal women.

Study Selection and Data Extraction  When available, meta-analyses and systematic reviews are emphasized in the review.

Data Synthesis  Bone mineral density (BMD) predicts fracture and can be used in combination with age to estimate absolute risk of fractures in postmenopausal white women. Hip BMD predicts hip fracture more strongly than other measurements of BMD. There are insufficient data to translate BMD results into risk of fracture for men and nonwhite women. The benefits of treatments to prevent fractures depend on BMD: women with osteoporosis have a greater risk of fractures and greater benefit from treatments than women without osteoporosis.

Conclusions  Guidelines based on systematic reviews and a cost-effectiveness analysis have suggested that it is worthwhile to measure BMD in white women older than 65 years and perhaps to use risk factors to select younger postmenopausal women for densitometry. Other potential clinical applications of BMD that have not yet been adequately studied include screening men or nonwhite women, monitoring BMD in patients receiving treatment, and using BMD to identify patients who should be evaluated for secondary causes of osteoporosis.

Author Affiliations: The UCSF Coordinating Center (Drs Cummings and Black), Department of Medicine (Dr Cummings), and Department of Epidemiology and Biostatistics, University of California, San Francisco (Drs Cummings and Black); and Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Bates).

RELATED LETTER

Bone Densitometry Testing in Nonwhite Patients
Max P. Francois, Malcolm D. Reid, and William Rosner
JAMA. 2003;289(8):982.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Clinical Use of Bone Densitometry: Clinical Applications
David W. Bates, Dennis M. Black, and Steven R. Cummings
JAMA. 2002;288(15):1898-1900.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
Chakhtoura et al.
Eur J Endocrinol 2008;158:879-887.
ABSTRACT | FULL TEXT  

Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole
Brufsky et al.
The Oncologist 2008;13:503-514.
ABSTRACT | FULL TEXT  

Loop Diuretic Use and Increased Rates of Hip Bone Loss in Older Men: The Osteoporotic Fractures in Men Study
Lim et al.
Arch Intern Med 2008;168:735-740.
ABSTRACT | FULL TEXT  

Early Determinants of Fractures in Rett Syndrome
Downs et al.
Pediatrics 2008;121:540-546.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

How We Maintain Bone Health in Early-Stage Breast Cancer Patients on Aromatase Inhibitors
Bao and Davidson
J Oncol Pract 2007;3:323-325.
FULL TEXT  

Implications Of Expanding Disease Definitions: The Case Of Osteoporosis
Herndon et al.
Health Aff (Millwood) 2007;26:1702-1711.
ABSTRACT | FULL TEXT  

Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity
Gomez-Ambrosi et al.
J. Clin. Endocrinol. Metab. 2007;92:3719-3727.
ABSTRACT | FULL TEXT  

Single-Site vs Multisite Bone Density Measurement for Fracture Prediction
Leslie et al.
Arch Intern Med 2007;167:1641-1647.
ABSTRACT | FULL TEXT  

Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis
Antoniucci et al.
J. Clin. Endocrinol. Metab. 2007;92:942-947.
ABSTRACT | FULL TEXT  

A 55-Year-Old Woman With Osteopenia
Cummings
JAMA 2006;296:2601-2610.
ABSTRACT | FULL TEXT  

Aromatase Inhibitors and Bone Health in Women With Breast Cancer
Chien and Goss
JCO 2006;24:5305-5312.
FULL TEXT  

Understanding Osteoporosis Prevalence in Hispanic Women
EVANS and TAYLOR
radtech 2006;77:451-459.
ABSTRACT | FULL TEXT  

Functional Significance of Bone Density Measurements in Children with Osteogenesis Imperfecta
Huang et al.
JBJS 2006;88:1324-1330.
ABSTRACT | FULL TEXT  

Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis
Bauer et al.
J. Clin. Endocrinol. Metab. 2006;91:1370-1375.
ABSTRACT | FULL TEXT  

Cancer-treatment-induced bone loss, part 1
Michaud and Goodin
Am J Health Syst Pharm 2006;63:419-430.
ABSTRACT | FULL TEXT  

Longitudinal Changes in Forearm Bone Mineral Density in Women and Men Aged 45-84 Years: The Tromso Study, a Population-based Study
Emaus et al.
Am J Epidemiol 2006;163:441-449.
ABSTRACT | FULL TEXT  

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
Lonning
Ann Oncol 2006;17:217-225.
ABSTRACT | FULL TEXT  

In Reply:
Lonning and Geisler
JCO 2005;23:9434-9435.
FULL TEXT  

Urinary Osteocalcin Is a Useful Marker for Monitoring the Effect of Alendronate Therapy
Ivaska et al.
Clin. Chem. 2005;51:2362-2365.
FULL TEXT  

Genetic Liability to Fractures in the Elderly
Michaelsson et al.
Arch Intern Med 2005;165:1825-1830.
ABSTRACT | FULL TEXT  

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
Lonning et al.
JCO 2005;23:5126-5137.
ABSTRACT | FULL TEXT  

Aromatase Inhibitors and Bone Loss: Risks in Perspective
Shapiro
JCO 2005;23:4847-4849.
FULL TEXT  

Bone Mineral Density and the Risk of Incident Nonspinal Fractures in Black and White Women
Cauley et al.
JAMA 2005;293:2102-2108.
ABSTRACT | FULL TEXT  

Primary Hyperparathyroidism Surgical Management Since the Introduction of Minimally Invasive Parathyroidectomy: Mayo Clinic Experience
Grant et al.
Arch Surg 2005;140:472-479.
ABSTRACT | FULL TEXT  

Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata
The Annals of Pharmacotherapy 2005;39:668-677.
ABSTRACT | FULL TEXT  

Impact of Pharmacist-Led Community Bone Mineral Density Screenings
Summers and Brock
The Annals of Pharmacotherapy 2005;39:243-248.
ABSTRACT | FULL TEXT  

Exemestane for Breast Cancer Prevention: A Feasible Strategy?
Lonning
Clin. Cancer Res. 2005;11:918s-924s.
ABSTRACT | FULL TEXT  

Protection of Bone Mass by Estrogens and Raloxifene during Exercise-Induced Weight Loss
Gozansky et al.
J. Clin. Endocrinol. Metab. 2005;90:52-59.
ABSTRACT | FULL TEXT  

Recommendations for Optimal Care of the Fragility Fracture Patient to Reduce the Risk of Future Fracture
Bouxsein et al.
J Am Acad Orthop Surg 2004;12:385-395.
ABSTRACT | FULL TEXT  

Classification Algorithms for Hip Fracture Prediction Based on Recursive Partitioning Methods
Jin et al.
Med Decis Making 2004;24:386-398.
ABSTRACT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT  

A test of Ockham's razor: implications of conjugated linoleic acid in bone biology
Watkins et al.
Am. J. Clin. Nutr. 2004;79:1175S-1185S.
ABSTRACT | FULL TEXT  

Clinical Considerations in Premenopausal Osteoporosis
Gourlay and Brown
Arch Intern Med 2004;164:603-614.
ABSTRACT | FULL TEXT  

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone et al.
NEJM 2004;350:1189-1199.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Hillner et al.
JCO 2003;21:4042-4057.
ABSTRACT | FULL TEXT  

The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Black et al.
NEJM 2003;349:1207-1215.
ABSTRACT | FULL TEXT  

Bone Densitometry Testing in Nonwhite Patients
Francois et al.
JAMA 2003;289:982-982.
FULL TEXT  

Clinical Use of Bone Densitometry: Clinical Applications
Bates et al.
JAMA 2002;288:1898-1900.
ABSTRACT | FULL TEXT